GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Granulocyte macrophage colony-stimulating factor (GM-CSF) is an immunostimulant and
preliminary data suggests it may change the natural history of prostate cancer and melanoma.
This study looks at ability of GM-CSF to alter disease progression in women who have
recurrent but asymptomatic recurrence of their ovarian cancer.